| Literature DB >> 35822027 |
Helen E Collins1, Mariame Selma Kane2, Silvio H Litovsky3, Victor M Darley-Usmar2, Martin E Young4, John C Chatham2, Jianhua Zhang2.
Abstract
Transmission electron microscopy (TEM) has long been an important technique, capable of high degree resolution and visualization of subcellular structures and organization. Over the last 20 years, TEM has gained popularity in the cardiovascular field to visualize changes at the nanometer scale in cardiac ultrastructure during cardiovascular development, aging, and a broad range of pathologies. Recently, the cardiovascular TEM enabled the studying of several signaling processes impacting mitochondrial function, such as mitochondrial fission/fusion, autophagy, mitophagy, lysosomal degradation, and lipophagy. The goals of this review are to provide an overview of the current usage of TEM to study cardiac ultrastructural changes; to understand how TEM aided the visualization of mitochondria, autophagy, and mitophagy under normal and cardiovascular disease conditions; and to discuss the overall advantages and disadvantages of TEM and potential future capabilities and advancements in the field.Entities:
Keywords: aging; autophagy; heart; heart failure; mitochondria; mitophagy; myocardial infarction; transmission electron microscopy
Year: 2021 PMID: 35822027 PMCID: PMC9261312 DOI: 10.3389/fragi.2021.670267
Source DB: PubMed Journal: Front Aging ISSN: 2673-6217
Figure 1Timeline of peer-reviewed cardiovascular publications utilizing transmission electron microscopy to examine cardiac ultrastructure. Data taken from Pubmed analytics using a search of “Transmission electron microscopy” and “heart.” Data presented were taken from 2000-present.
Figure 2Example images of cardiac cellular structures examined using TEM studies from wild-type mouse hearts. (A) TEM image showing mitochondria surrounding a lipid droplet; (B) Magnification of Lipid droplet in (A); (C) TEM image of cardiac sarcomeric structure; (D) TEM image of SR-mitochondria connections. Red arrows depict mitochondria and white arrow depicts SR; (E) TEM image showing glycogen deposits (highlighted in red box); (F) TEM image of a nucleus; (G) TEM image of gap junctions (gap junctions depicted by red arrows); and (H) TEM image showing a mitochondrial derived vesicle budding from larger mitochondria (highlighted by red box). Images are unpublished images from Zhang lab studies. Scale bar depicts 500 nm.
Common technical problems with TEM and strategies for improvement.
|
|
|
|
|---|---|---|
| Under fixation of tissue | Tissue distortion and poor-quality staining | Make sure tissue is correct dimensions to allow for appropriate infiltration of fixative. |
| Over fixation of tissue | Tissue distortion and poor-quality staining | Reduce time that tissue is in fixative. |
| Chemical fixation-induced sample contamination | Poor-quality Images | Use freshly made fixative solutions. |
| Inadequate washing | Speckled areas on tissue | Clean bottles used to store Osmium tetroxide with H2O2 and add some H2O2 to help prevent reduction of osmium tetroxide by glutaraldehyde. |
| Formation of precipitates (due to uranyl acetate and lead citrate) | Small black dots and speckled areas on tissue | Check pH of solutions. The pH of the uranyl acetate containing solution may need to be adjusted. |
| Inadequate resin filtration | Tears and holes in tissue | Make sure to perform solvent substitution. |
| Toluidine blue staining | Too dark or too light | Too dark—rinse with water |
| Imaging sections with high beam intensity | Tissue will break and curl up leaving the grid unusable | Set beam at lower intensities and slowly increase when necessary. |
| Image artifacts mistaken for real changes | Will lead to generation of inaccurate analyses and findings. | Learn and know how to identify common TEM artifacts. |
| Analyses performed on a small number of images | May not reflect an accurate representation of what is occurring in specific tissue sample. | Take a minimum of 10–20 images per magnification of interest for analysis |
| Using both longitudinal and cross-sectional images for analyses | May not reflect an accurate representation of what is occurring in specific tissue sample. | Be sure to take images in longitudinal plane (unless looking at fiber changes) for analyses. |
Figure 3Tissue preparation for TEM studies.
Cardiac ultrastructures identified, examined, and measured using TEM.
|
|
|
|
|---|---|---|
| Mitochondria | Number, size, area, aspect ratio, and contact sites with SR | Searls et al., |
| Mitochondrial-derived vesicles (MDV) | Presence, distribution, and size | Cadete et al., |
| Sarcomeres/myofibrillar structure | Structural integrity and sarcomere length | Searls et al., |
| SR | Structural integrity and proximity to mitochondria | Eisenberg et al., |
| Myelin bodies/endosomal bodies/apoptotic bodies | Presence | Gupta et al., |
| Nuclei/nuclear envelope | Structure, size, and chromatin condensation | Searls et al., |
| Autophagosomes/autophagic vacuoles/mitophagosomes | Number, size, and distribution | Wohlgemuth et al., |
| Lysosomes | Number, size, distribution | Carreira et al., |
| Lipid droplets | Number, size, proximity to autophagosomes and mitochondria | Searls et al., |
| Glycogen granules | Presence, distribution, size, and aggregation | Haemmerle et al., |
| Gap junctions/desmosomes | Presence and structural integrity | Hesketh et al., |
| Telocytes | Presence and distribution | Gherghiceanu and Popescu, |
Cardiac ultrastructure in hypertrophy, heart failure (HF), and hypertension.
|
|
|
|
|
|---|---|---|---|
| Dilated cardiomyopathic (DCM) hearts compared to ischemic (ICM) hearts | A large population of smaller | Quantitative morphometric measurement of mito cellular volume density (0.3 ICM vs. 0.6 DCM μm3/μm3) | Ahuja et al., |
| Patients with DCM (250 patients) | Ultrastructural changes in cardiac | % myofilament changes were scored and subdivided with focal derangement, diffuse myofilament lysis, replaced by smooth endoplasmic reticulum (ER) and replaced by large filamentous masses | Saito et al., |
| Cardiac ultrastructure in human endocardial biopsies in patients with chronic HF due to different etiology | Lysosomal storage diseases, mitochondrial cardiomyopathy, autophagic degeneration, and doxorubicin (Dox)-induced cardiomyopathy, exhibit general ↓ of myofibrils, vacuolar degeneration, accumulation of | No | Takemura et al., |
| Human DCM | The presence of | No | Gil-Cayuela et al., |
| Induced pluripotent stem cells (IPSCs) from patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) | Desmosome distortion (↑ in gap and total width), and ↑ | Desmosomal gap width 24 ->34 nm, total desmosome width 100 - >160 nm by ARVC, more gap width the more % LD containing cardiomyocytes | Caspi et al., |
| Phenylephrine (PE)-treated rat adult cardiac myocytes, rat LV after ascending aortic banding (HF), human HF patient LV subepicardial biopsy | Time-dependent changes (stages) occurred with | % for stages A, B, B–>C, C, and D, per TEM 12k× magnified field scored for ACM control vs. PE, for rat normal vs. HF, and human normal vs. HFrEF | Chaanine, |
|
|
|
|
|
| Guinea pig HF (8 weeks after ascending aortic constriction) | Av. mito length ~1 −>0.75 μm, | Goh et al., | |
| Cardiomyocyte expression of myotrophin in mice led to heart hypertrophy at 4 weeks of age and HF at 36 weeks. of age | At 16–24 weeks of age, | Scoring of changes (1–4) of mitochondria, myofibril and z-line, and cytoplasm/nucleus (0 to >45% changes initiation - progression - transition) | Gupta et al., |
| Rats with HF induced by volume overload | ↑ from ~10 −>~75% cardiomyocytes with apoptotic and mitochondrial changes | Treskatsch et al., | |
| Adiponectin-KO mice in response to sham or mTAB | Sham hearts contain | No | Jahng et al., |
| Mouse TAC | ↑ Number of | Mitophagy | Shirakabe et al., |
| Rat hearts containing truncated Titin | Accumulation of | Number of autophagic vacuoles/field from 1.5 -> 4.5 | Zhou et al., |
| Dox-induced cardiomyopathy in rat | Similar | No | Babaei et al., |
| Cardiomyocyte deletion of STIM1 (KO) compare to WT (c) | DCM at 36 weeks of age. | Av. number of LD/4400× grid2 2 (c), 3.3 (KO) | Collins et al., |
| Rat hearts in response to angiotensin II (Ang II) and effects of simvastatin (SIM) | Graded appearance; quantified: mito length, No. of swollen mito (2–8/field), mito with vacuolization, LD, autophagosome, mitophagosome, and lysosome per field | Hsieh et al., | |
| Cathepsin S KO mice and/or Ang II administration | ↑ | No | Pan et al., |
Highlighted in bold are the subcellular structures observed by transmission electron microscopy (TEM).
Cardiac ultrastructure in ischemia/reperfusion (I/R) and myocardial infarction (MI).
|
|
|
|
|
|---|---|---|---|
| A rat model of MI | No | Wu et al., | |
| A mouse model of MI | ↑ Large vacuoles resemble | No | Kanamori et al., |
| MI in GFP-LC3 transgenic mice, treated with starvation and/or bafilomycin | Time-dependent ↑ of | No | Kanamori et al., |
| Post-MI treatment of resveratrol | ↑ | No | Kanamori et al., |
Highlighted in bold are the subcellular structures observed by TEM.
Cardiac ultrastructure metabolic-induced cardiac perturbations.
|
|
|
|
|
|---|---|---|---|
| Rats 4 and 8 months after STZ (60 mg/kg)-induced diabetes | No changes noted for | Sarcomere lengths quantified to be ~2 μm for both ventricle and papillary muscle at 4 or 8 months after STZ | Howarth et al., |
| Rats 7 weeks after STZ (65 mg/kg)-induced diabetes (7 weeks) and the effect of exercise (starts 2 weeks before STZ until end of study) examined | ↑ Damaged | Grading: 1, fully intact; 2, <50% disruption of inner mito membranes; 3, >50% disruption of inner membranes; 4, disruption of the outer membrane only; 5, disruption of both inner and outer membranes | Searls et al., |
| Rabbit (24 prepubertal New Zealand white) with HFD 3 months | ↑ | No | Sibouakaz et al., |
| Wild-type (WT), atg7f/f:αMHC-cre, or Parkin KO mice | HFD for 2 months produced bigger | 0.3 μm in WT, 1.0 μm in Atg7f/f:αMHC-cre, and 0.7 μm in Parkin KO mice | Tong et al., |
| Rat late exercise preconditioning (LEP), exhaustive exercise (EE), and the use of wortmannin i.p. (W) | Changes in cardiac | No | Yuan and Pan, |
Highlighted in bold are the subcellular structures observed by TEM.
Aging-induced cardiac perturbations.
|
|
|
|
|
|---|---|---|---|
| Male Fisher 344 rats 6 and 26 months | ↑ Cardiac | Mean fractional autophagic vesicle volume is increased from 0.7 to 1.4 by caloric restriction in 26-month-old rat heart | Wohlgemuth et al., |
| Male mice 4–24 months | Dysregulation of | No | Bonda et al., |
| Male mice 4 vs. 24 months | ↓ | Mi/myo from 0.35 to 0.28, mf/myo from 0.53 to 0.51, sp/myo from 0.10 to 0.19 from 4 to 24 months, spermidine restore these values | Eisenberg et al., |
| Male mice 4–24 months | Elongated | Mitochondrial area increased from 0.6 to 1 μm2 | Liang et al., |
Highlighted in bold font are the subcellular structures observed by TEM.
Autophagy and mitophagy in the heart (not included in previous tables).
|
|
|
|
|
|---|---|---|---|
| HL-1 cells under starvation | Starvation ↑ autophagosomes and ↓ mitochondrial content | Mitochondria/cell sections ↓ from 35 to 11 after 3.5 h starvation, and 5 μM CsA correct it to 30; | Carreira et al., |
| Adult cardiac progenitor cells in differentiation medium | Knockdown of the mitophagy receptors, | No | Lampert et al., |
| Drosophila muscle and heart | Knockdown of | No | Xu et al., |
| Hearts of the Parkin knockout (KO) mice | Smaller mitochondria, ↑Fis1 and ↓ dynamin-related protein 1 (Drp1), oxygen consumption normal in isolated mitochondria. In response to MI, more mitochondrial damage, and accumulation of autophagosomes in Parkin KO mouse hearts at the border zone | Mean mito area 0.5−>0.4 μm2 | Kubli et al., |
| Tamoxifen inducible Parkin KO ( | Heart mito in postnatal day 21 (P21) WT mice exhibited ovoid structure compared to P1. Parkin KO P21 mito did not differ from P1, but with abundant lipid droplets (LD) | No | Gong et al., |
| Whole-body Parkin KO or cardiac (αMHC) Parkin overexpression (OE) | Using a polymerase γ (POLG) mutant mouse that develop cardiac hypertrophy, it was shown that neither Parkin KO or cardiac Parkin OE changed the POLG phenotype, whereas megamitochondria appear to be present in the POLG and the POLG:Parkin OE mice | No | Woodall et al., |
| Dystrophin-deficient mice (mdx) | ↓ Levels of LC3, P62, Pink1, and Parkin in the mitochondrial fraction; ↑ cristae-damaged mitochondria; ↓ the number of mitochondria in autophagosomes in response to 15 mg/kg DNP (a mitochondrial uncoupler) | At 3–4 months % mitochondria with loss of cristae 0.2−>1/4, at 12 months 1−>3.5 wt vs. mdx | Kang et al., |
| AC16 cells with Dox | ↑ Cristae-damaged mitochondria | No | Yin et al., |
| Rats with lentiviral pigment epithelial-derived factor (PEDF) followed by acute MI (AMI) | AMI ↓ the numbers of mitochondria and ↑ the numbers of mitophagosomes, PEDF further enhanced the change. | Number of | Li et al., |
Quantification of autophagosomes and mitophagosomes are in bold.
Figure 4Number of peer-reviewed cardiovascular publications utilizing transmission electron microscopy to examine cardiovascular autophagy (A) and mitophagy (B). Data taken from Pubmed analytics using a search of “Transmission electron microscopy,” “heart,” and “autophagy” or “mitophagy” for year 2000 to present.
Mitochondrial quality control studies using TEM.
|
|
|
|
|
|---|---|---|---|
| Overexpression (OE) of PGC1α in cardiomyocytes | Adeno-PGC1α in rat neonatal cardiac myocyte resulted in enlarged mitochondria, with ↑ oxygen consumption; MHC-PGC1α mice are fatter, with dilated cardiomyopathy, and ↑ numerous and enlarged mitochondria | Mean total mitochondrial area/total cytoplasmic area in adeno-PGC1α cells was 57% higher relative to control (0.36 vs. 0.23) | Lehman et al., |
| PGC1α whole body knockout (KO) at 3 months | No specific changes in hypertrophy, dilatation, or fibrosis; normal mitochondria volume despite changes in mitochondrial function | % Mitochondrial volume remained to be ~40% | Arany et al., |
| PGC1β−/− and double KO (DKO) of PGC1α and 1β | PGC1β−/− appear normal, while DKO resulted in neonatal lethality with heart failure (HF). TEM of the E16.5, E17.5, PD0.5 hearts show lack of increase of heart size showed ↑ of mitochondria in WT, single KO, but not DKO hearts; ↓ mitochondrial volume density and normal myofibril volume density at PD0.5 | Mitochondrial volume density from 0.3 to 0.1; myofibril volume density 0.35 μm3/μm3 | Lai et al., |
| Mck-cre mediated PGC1β KO with PGC1α-/– | 30% levels of PGC1β mRNA at birth in the heart. Mice start to die at 5 weeks of age with 14% survival by 20 weeks. Progressive cardiomyopathy starting at 1 week of age. Mitochondria appear normal postnatal day 1, fragmentation and elongation abnormality at 1 week, and progressively worsen and also observed ↓ mtDNA, mito protein, and mito function. ↓ Mfn1, Mfn2, Opa1, Fis1 and Drp1, Mitophagosomes were not observed. | No | Lai et al., |
| Tamoxifen inducible PGC1β cardiac KO with PGC1α-/– | 1 month after tamoxifen, TEM shows normal average mitochondrial size or volume density, while ↑ the numbers of mitochondria with cristae damage, with ↓ expression of CDP-diacylglycerol synthase 1, which catalyzes a key step in cardiolipin synthesis | No | Lai et al., |
| Atgl-KO mice | ↑ mitochondrial diameter, lipid droplet (LD) and glycogen granule numbers by TEM (10-week-old female), | Mito diameter ~0.55 to ~0.62 μm (~18%) | Haemmerle et al., |
| αMHC-PGC1α OE through knocking into the ROSA26 locus in both WT and G3Terc−/− (third generation of telomerase deficient) background | The G3Terc−/− mice have ↓ PGC1α levels and deficient mitochondrial function. | Quantitation were performed at 3 months (but not 10 and 12 months): | Zhu et al., |
| Estrogen-related receptor (ERR) α and ERRγ DKO with lethal cardiomyopathy | At P16 distorted myofibrils, loss of clear boundaries between the A band and I band, fragmented mitochondria with loss of cristae, ↓ mitochondrial proteins. | Mito Size (μm2): WT ~0.65, DKO ~0.2 | Wang et al., |
| KO of ERRα and ERRγ using AAV9-cTnT-cre | At 5 weeks, there are vesicle engulfed organelles, elongated or fragmented mitochondria and LD in the DKO heart | No | Sakamoto et al., |
Additional mitochondrial fission and fusion studies in the heart using TEM.
|
|
|
|
|
|---|---|---|---|
| Mdivi-1 did not change mitochondrial morphology as assessed by TEM, while | Percent mitochondria that are >2 μm or 1 sarcomere in length, 3.6% (vehicle) vs. 14.5% (with mdivi-1) | Ong et al., | |
| Drp (Myh6-cre) KO in the early postnatal days | Compromised LV function at postnatal day 7, decreased mitochondrial respiratory activity. Myofibrils appeared unaffected. | Tomography study with 3D reconstruction measurement demonstrated that Drp1 KO heart has: | Kageyama et al., |
| Cardiac Drp1-KO ( | Dilated cardiomyopathy (DCM) and heart failure (HF) 6–8 weeks after KO. Mitochondria have preserved cristae; however, they were larger and more elongated. In this study, mitochondrial autophagy and mitochondrial stress were assessed using p62, LC3, LONP2, AFG3L2, and Hsp60 Western blots. | ↑Mean area ctl 0.9, 3 weeks 1.8, 6 weeks 1.8 μm2
| Song et al., |
| Parkin and Drp1 DKO mice ( | Parkin KO or overexpression (OE) did not result in cardiac dysfunction over 20 weeks. TEM at 6 weeks after Parkin KO look normal, Myh6-Parkin transgenic mice at 30 weeks did not show abnormalities in mito content, mito area and aspect ratio. TEM showed that Drp1 KO exhibit loss of mitochondria 6 weeks after Drp1 deletion, Parkin/Drp1 DKO delays cardiomyopathy of the Drp1 KO, and partially restore mitochondrial content | Mito content (% total cell): WT: 50%, Parkin KO: 50%, Drp1 KO: 30%, DKO: 42% | Song et al., |
| Whole-body Opa1 heterozygous knockout (KO) (+/–) mice | Cardiac dysfunction at 12 months but not 3 months | No | Chen L. et al., |
| Whole-body Opa1 heterozygous KO(+/–) mice | At 6 months, no change of cardiac function, but | ↑ Mean size of mitochondria: | Chen L. et al., |
| Cardiac specific Mfn2 KO hearts ( | Cardiac dysfunction at 17 months, and increased sensitivity to I/R injury at 6 months. At 4 months, | ↑ Mito area 0.65 μm2 WT, 1.05 μm2 in MFN2 CKO heart | Zhao et al., |
| Mfn1 and Mfn2 KO (Myh6 “turbo” cre) | Mfn2 KO exhibit | Ctl vs. Mfn2 | Chen Y. et al., |
| Using Myh6-cre to delete Mfn1 starting embryonic day 9.5 | ↑ Small, fragmented mitochondria; | ↓ Cross-sectional mito area 52–32 μm2
| Papanicolaou et al., |
| Cardiac Mfn1/2 DKO ( | While Drp1 KO heart has | ↓ Mito area ctl 0.75 μm2, 3 weeks 5 μm2, 6 weeks 0.4 μm2
| Song et al., |
| Cardiac (Myh6) OE of Mfn2, Mfn2-AA | Mfn2-AA mice have smaller, abnormally shaped mitochondria in the heart starting at 3 weeks of age, associated with | 3 weeks: Mito content | Gong et al., |
| Cardiac Mfn1/2 DKO ( | Mfn DKO mice are more resistant to I/R injury, have smaller mitochondria, the presence of cristae-disrupted and fragmented interfibrillar mitochondria, maximal respiration | ↓ Mito area ctl 0.55–0.42 μm2 (5 weeks KO) | Hall et al., |
| Mfn2 KO (cardiac- Myh6 “turbo” cre) 8–10 weeks | Extensive 3D analyses of mito volume, roundness, elongation, flatness, minimum mito-jSR distance | ↑ Volume 0.6 vs. 0.85 μm3; | Beikoghli Kalkhoran et al., |
| OE of Mfn2 (ad-Mfn2 vs. control of ad-ctl) in neonatal rat cardiomyocytes | No change of mitochondrial number, length, size, aspect ratio, or number of mitophagic vacuoles. However, addition of Ang II resulted in an accumulation of mitophagic vacuoles and increased mitochondrial size, indicative of increased mitochondrial damage | Mito autophagy (%) 0.05 | Xiong et al., |